Inhibition of JNK signalling mediates PPAR-dependent protection against intrahepatic cholestasis by fenofibrate

被引：46

作者：

Dai, Manyun ^{[1
]}

Yang, Julin ^{[2
]}

Xie, Minzhu ^{[1
]}

Lin, Jiao ^{[1
]}

Luo, Min ^{[1
]}

Hua, Huiying ^{[1
]}

Xu, Gangming ^{[1
]}

Lin, Hante ^{[1
]}

Song, Danjun ^{[1
]}

Cheng, Yuqing ^{[3
]}

Guo, Bin ^{[3
]}

Zhao, Jinshun ^{[1
]}

Gonzalez, Frank J. ^{[4
]}

Liu, Aiming ^{[1
]}

机构：

[1] Ningbo Univ, Med Sch, Ningbo 315211, Zhejiang, Peoples R China

[2] Ningbo Coll Hlth Sci, Ningbo, Zhejiang, Peoples R China

[3] Hunan Normal Univ, Changsha, Hunan, Peoples R China

[4] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2017年 / 174卷 / 18期

基金：

中国国家自然科学基金;

关键词：

PRIMARY BILIARY-CIRRHOSIS; ACTIVATED RECEPTOR-ALPHA; PRIMARY SCLEROSING CHOLANGITIS; NF-KAPPA-B; CHOLESTEROL; 7-ALPHA-HYDROXYLASE; DOWN-REGULATION; CONCISE GUIDE; BILE-ACIDS; URSODEOXYCHOLIC ACID; ANIMAL-MODELS;

D O I：

10.1111/bph.13928

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background and PurposeFenofibrate, a PPAR agonist, is the most widely prescribed drug for treating hyperlipidaemia. Although fibrate drugs are reported to be beneficial for cholestasis, their underlying mechanism has not been determined. Experimental ApproachWild-type mice and Ppar-null mice were pretreated orally with fenofibrate for 3 days, following which -naphthylisothiocyanate (ANIT) was administered to induce cholestasis. The PPAR agonist WY14643 and JNK inhibitor SP600125 were used to determine the role of PPAR and the JNK pathway, respectively, in cholestatic liver injury. The same fenofibrate regimen was applied to investigate its beneficial effects on sclerosing cholangitis in a DDC-induced cholestatic model. Key ResultsFenofibrate, 25mgkg(-1) twice a day, totally attenuated ANIT-induced cholestasis and liver injury as indicated by biochemical and histological analyses. This protection occurred in wild-type, but not in Ppar-null, mice. Alterations in bile acid synthesis and transport were found to be an adaptive response rather than a direct effect of fenofibrate. WY14643 attenuated ANIT-induced cholestasis and liver injury coincident with inhibition of JNK signalling. Although SP600125 did not affect cholestasis, it inhibited liver injury in the ANIT model when the dose of fenofibrate used was ineffective. Fenofibrate was also revealed to have a beneficial effect in the sclerosing cholangitis model. Conclusions and ImplicationsThese data suggest that the protective effects of fenofibrate against cholestasis-induced hepatic injury are dependent on PPAR and fenofibrate dose, and are mediated through inhibition of JNK signalling. This mechanism of fenofibrate protection against intrahepatic cholestasis may offer additional therapeutic opportunities for cholestatic liver diseases.

引用

页码：3000 / 3017

页数：18

共 67 条

[1] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Enzymes [J].

Alexander, Stephen P. H. ;

Fabbro, Doriano ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :6024-6109

[2] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Nuclear hormone receptors [J].

Alexander, Stephen P. H. ;

Cidlowski, John A. ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :5956-5978

[3] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Transporters [J].

Alexander, Stephen P. H. ;

Kelly, Eamonn ;

Marrion, Neil ;

Peters, John A. ;

Benson, Helen E. ;

Faccenda, Elena ;

Pawson, Adam J. ;

Sharman, Joanna L. ;

Southan, Christopher ;

Davies, Jamie A. ;

Aldrich, R. ;

Attali, B. ;

Back, M. ;

Barnes, N. M. ;

Bathgate, R. ;

Beart, P. M. ;

Becirovic, E. ;

Biel, M. ;

Birdsall, N. J. ;

Boison, D. ;

Brauner-Osborne, H. ;

Broeer, S. ;

Bryant, C. ;

Burnstock, G. ;

Burris, T. ;

Cain, D. ;

Calo, G. ;

Chan, S. L. ;

Chandy, K. G. ;

Chiang, N. ;

Christakos, S. ;

Christopoulos, A. ;

Chun, J. J. ;

Chung, J. -J. ;

Clapham, D. E. ;

Connor, M. A. ;

Coons, L. ;

Cox, H. M. ;

Dautzenberg, F. M. ;

Dent, G. ;

Douglas, S. D. ;

Dubocovich, M. L. ;

Edwards, D. P. ;

Farndale, R. ;

Fong, T. M. ;

Forrest, D. ;

Fowler, C. J. ;

Fuller, P. ;

Gainetdinov, R. R. ;

Gershengorn, M. A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :6110-6202

[4] Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans [J].

Bergman, AJ ;

Murphy, G ;

Burke, J ;

Zhao, JJ ;

Valesky, R ;

Liu, L ;

Lasseter, KC ;

He, WL ;

Prueksaritanont, T ;

Qiu, Y ;

Hartford, A ;

Vega, JM ;

Paolini, JE .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :1054-1062

[5] Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review [J].

Boonstra, Kirsten ;

Beuers, Ulrich ;

Ponsioen, Cyriel Y. .

JOURNAL OF HEPATOLOGY, 2012, 56 (05) :1181-1188

[6] Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].

Broome, U ;

Olsson, R ;

Loof, L ;

Bodemar, G ;

Hultcrantz, R ;

Danielsson, A ;

Prytz, H ;

SandbergGertzen, H ;

Wallerstedt, S ;

Lindberg, G .

GUT, 1996, 38 (04) :610-615

[7] Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid [J].

Carbone, Marco ;

Mells, George F. ;

Pells, Greta ;

Dawwas, Muhammad F. ;

Newton, Julia L. ;

Heneghan, Michael A. ;

Neuberger, James M. ;

Day, Darren B. ;

Ducker, Samantha J. ;

Sandford, Richard N. ;

Alexander, Graeme J. ;

Jones, David E. J. .

GASTROENTEROLOGY, 2013, 144 (03) :560-+

[8] Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes [J].

Cheung, A. C. ;

Lapointe-Shaw, L. ;

Kowgier, M. ;

Meza-Cardona, J. ;

Hirschfield, G. M. ;

Janssen, H. L. A. ;

Feld, J. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :283-293

[9] Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice:: an experimental study [J].

Cindoruk, Mehmet ;

Kerem, Mustafa ;

Karakan, Tarkan ;

Salman, Bulent ;

Akin, Okan ;

Alper, Murat ;

Erdem, Ozlem ;

Uenal, Selahattin .

BMC GASTROENTEROLOGY, 2007, 7 (1)

[10] High lifetime risk of cancer in primary sclerosing cholangitis [J].

Claessen, Marian M. H. ;

Vleggaar, Frank P. ;

Tytgat, Kristien M. A. J. ;

Siersema, Peter D. ;

van Buuren, Henk R. .

JOURNAL OF HEPATOLOGY, 2009, 50 (01) :158-164

← 1 2 3 4 5 6 7 →